UBS Maintains Buy on Insmed, Raises Price Target to $58
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Trung Huynh maintains a Buy rating on Insmed (NASDAQ:INSM) and raises the price target from $46 to $58.
May 29, 2024 | 1:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Trung Huynh maintains a Buy rating on Insmed and raises the price target from $46 to $58.
The raised price target and maintained Buy rating from a reputable analyst at UBS is likely to positively impact Insmed's stock price in the short term as it reflects increased confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100